Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella

Journal of Microbiology, Immunology and Infection

Volumn 39, Issue 6, 2006, Pages 496-502

  Huang, Shie Shian ^a   Lee, Ming Hsun ^a   Leu, Hsieh Shong ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Bacteremia; Beta lactamase; Carbapenems

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; FLOMOXEF; GENTAMICIN; GLUCOCORTICOID; IMIPENEM; ANTIINFECTIVE AGENT; BETA LACTAMASE; CARBAPENEM DERIVATIVE;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM CULTURE; CLINICAL FEATURE; CONTROLLED STUDY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; FEMALE; HUMAN; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATHOGENESIS; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL RATE; TERTIARY HEALTH CARE; TREATMENT OUTCOME; COMPARATIVE STUDY; ENTEROBACTER INFECTION; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; TAIWAN;

ADULT; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; CARBAPENEMS; CEFTAZIDIME; CIPROFLOXACIN; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI; FEMALE; HUMANS; KLEBSIELLA; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAIWAN; TREATMENT OUTCOME;

EID: 33847738656     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Arpin C, Dubois V, Coulange L, Andre C, Fischer I, Noury P, et al. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in community and private health care centers. Antimicrob Agents Chemother 2003;47:3506-14.
2. Paterson DL, Ko WC, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001;39:2206-12.
3. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests. 7th ed. Approved standard. NCCLS document M2-A7. Wayne, Pa: National Committee for Clinical Laboratory Standards; 2000.
4. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 5th ed. Approved standard. NCCLS document M7-A5. Wayne, Pa: National Committee for Clinical Laboratory Standards; 2000.
5. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Twelfth informational supplement. NCCLS document M100-S12. Wayne, Pa: National Committee for Clinical Laboratory Standards; 2002.
6. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004;39:31-7.
7. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004;48:4574-81.
8. Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001;45:3548-54.
9. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections 1988. Z Arztl Fortbild (Jena) 1991;85:818-27. [In German].
10. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983;11:315-7.
11. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933-51.
12. Mammeri H, Poirel L, Bemer P, Drugeon H, Nordmann P. Resistance to cefepime and cefpirome due to a 4-amino-acid deletion in the chromosome-encoded AmpC beta-lactamase of a Serratia marcescens clinical isolate. Antimicrob Agents Chemother 2004;48:716-20.
13. Raad, II, Sabbagh MF. Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review. Clin Infect Dis 1992;14:75-82.
14. Lode H. Pharmacokinetics and clinical results of parenterally administered new quinolones in humans. Rev Infect Dis 1989;11 Suppl 5:S996-1004.
15. Chen CC, Sun YT, Chen JJ, Chiu KT. TNF-alpha-induced cyclooxygenase-2 expression in human lung epithelial cells: involvement of the phospholipase C-gamma 2, protein kinase C-alpha, tyrosine kinase, NF-kappa B-inducing kinase, and I-kappa B kinase 1/2 pathway. J Immunol 2000;165:2719-28.
16. Mimoz O, Jacolot A, Padoin C, Tod M, Samii K, Petitjean O. Cefepime and amikacin synergy in vitro and in vivo against a ceftazidime-resistant strain of Enterobacter cloacae. J Antimicrob Chemother 1998;41:367-72.
17. Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005;352:380-91.
18. Cosgrove SE, Kaye KS, Eliopoulous GM, Carmeli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002;162:185-90.